Evidence map›Paper›PMID 42864567›Full record

ArticleAnnals of surgical oncology2026

Primary Breast Angiosarcoma: Clinicopathologic Features and Oncologic Outcomes.

Rick D Vavolizza, Aparna Subramaniam, Min Yi, Emma Wingate, Alex N Perez, Emily Keung, Christina L Roland, Keila Torres, Christopher P Scally, Heather Lyu and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Rick D VavolizzaDepartment of Breast Surgical Oncology, University of Texas MD Anderson, Houston, TX, USA.
Aparna SubramaniamDepartment of Sarcoma Medical Oncology, University of Texas MD Anderson, Houston, TX, USA.
Min YiDepartment of Breast Surgical Oncology, University of Texas MD Anderson, Houston, TX, USA.
Emma WingateDepartment of Breast Surgical Oncology, University of Texas MD Anderson, Houston, TX, USA.
Alex N PerezDepartment of Pathology, Vanderbilt University Medical Center, Nashville, TN, USA.
Emily KeungDepartment of Surgical Oncology, University of Texas MD Anderson, Houston, TX, USA.
Christina L RolandDepartment of Surgical Oncology, University of Texas MD Anderson, Houston, TX, USA.
Keila TorresDepartment of Surgical Oncology, University of Texas MD Anderson, Houston, TX, USA.
Christopher P ScallyDepartment of Surgical Oncology, University of Texas MD Anderson, Houston, TX, USA.
Heather LyuDepartment of Surgical Oncology, University of Texas MD Anderson, Houston, TX, USA.
Alison YoderDepartment of Radiation Oncology, University of Texas MD Anderson, Houston, TX, USA.
Devarati MitraDepartment of Radiation Oncology, University of Texas MD Anderson, Houston, TX, USA.
Ahsan S FarooqiDepartment of Radiation Oncology, University of Texas MD Anderson, Houston, TX, USA.
Andrew J BishopDepartment of Radiation Oncology, University of Texas MD Anderson, Houston, TX, USA.
B Ashleigh GuadagnoloDepartment of Radiation Oncology, University of Texas MD Anderson, Houston, TX, USA.
Alex LazarDepartment of Pathology, University of Texas MD Anderson, Houston, TX, USA.
Vinod RaviDepartment of Sarcoma Medical Oncology, University of Texas MD Anderson, Houston, TX, USA.
Kelly K HuntDepartment of Breast Surgical Oncology, University of Texas MD Anderson, Houston, TX, USA.
Heather A LillemoeDepartment of Breast Surgical Oncology, University of Texas MD Anderson, Houston, TX, USA. halillemoe@mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary breast angiosarcoma (PBA) is rare, and limited data exist because studies often combine primary and secondary angiosarcoma patients.

methodsFor patients with PBA who received care at a comprehensive cancer center from 1991 to 2025 and underwent surgical resection, this retrospective study collected and analyzed clinicopathologic features, treatment patterns, and survival data.

resultsAmong 176 patients, 138 met the inclusion criteria. The median age was 40 years (interquartile range [IQR], 32-49 years). Most of the tumors were high grade with a median size of 6.5 cm. Most of the patients underwent mastectomy (88%). Among the 50 patients (36%) who underwent axillary surgery, only 6 patients had nodal metastases. Multimodal treatment was performed for 121 patients (88%), including chemotherapy/surgery (n = 46, 38%), radiation therapy (RT)/surgery ( = 15, 12%), and chemotherapy/RT/surgery (n = 60, 50%). The median follow-up time was 3.7 years. The median overall survival (OS) was 6 years (IQR, 3.5-8.7 years), and the 5-year OS was 58%. Recurrence was experienced by 62% of the patients, with a median recurrence-free survival (RFS) of 3 years (IQR, 1.4-7.7 years). Most of the recurrences were distant (79%), with 14% of the patients experiencing local recurrence only. Tumor size larger than 5 cm and high-grade histology were independently associated with lower OS. When stratified by treatment modality, there was no statistical difference in OS (p = 0.475).

conclusionsPrimary breast angiosarcoma arises in women with a median age of 40 years, and large, high-grade tumors are associated with worse survival outcomes. Distant recurrence is common, whereas nodal metastases and local failure are not. Most of the patients in this study received multimodal therapy without a clear impact of modality on OS. However, further collaborative studies may be required to assess the impact of modality on disease outcomes.

Indexed as

Multimodal treatmentPrimary breast angiosarcomaSurvival outcomes

Identifiers

PMID42864567

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.